cbdMD announced today an expansion of its topical product line with the launch of ‘Premium Relieve’, a product that combines the pain-fighting power of Lidocaine with Superior Broad Spectrum CBD extracts – leading to total wellness in one unique topical formula.
CHARLOTTE, N.C., Nov. 12, 2020 /PRNewswire-PRWeb/ — cbdMD, Inc. (NYSE American: YCBD, YCBD PR A) (the “Company”), one of the leading, and most highly trusted and recognized cannabidiol (CBD) brands, announced today an expansion of its topical product line with the launch of ‘Premium Relieve’, a product that combines the pain-fighting power of Lidocaine with Superior Broad Spectrum CBD extracts – leading to total wellness in one unique topical formula.
Available in a roll-on applicator or spray, Premium Relieve combines the proven powers of Lidocaine (4%) with cbdMD’s Superior Broad Spectrum formula, providing temporary relief from minor muscle aches and pains.
Premium Relieve joins a diverse offering of topical products featuring high profile over-the-counter (OTC) pain relief ingredients fused with cbdMD’s unique hemp extract blend, including:
Premium Freeze Pain Relieving Formula (‘2020 Product of the Year’ Winner: CBD Topical) – cbdMD’s award-winning Freeze gel offers the proven pain-relief properties of menthol, blended with the power of domestically sourced CBD, to provide temporary pain relief while working to ease aching muscles and joints.
Premium Recover Pain Relieving Formula – cbdMD’s Recover combines pain-relieving agent Histamine Dihydrochloride (0.05%) with the whole-body benefits of cbdMD’s Superior Broad Spectrum CBD formula into a unique, richly moisturizing cream that’s great for temporary relief of pain and muscle aches, without any of the smell.
cbdMD’s release of Premium Relieve marks an advancement in the topical market as it is one of the few CBD topicals available in aerosol spray form, utilizing a unique Bag-on-Valve Technology that allows for spraying at any angle and covering difficult-to-reach areas. In addition, Premium Relieve contains the most abundant CBD content of any Lidocaine-infused topical currently on the market.
“Topicals have never been more popular for consumers, with more and more products adding CBD to their formulas these days,” said Ken Cohn, Chief Marketing Officer at cbdMD. “At cbdMD, we’re revolutionizing the topical market by introducing innovative products that continue to lead in each category. With ‘Premium Relieve’, we are proud to now offer an expanded topicals line that is well-rounded and balanced, with broad appeal to not only health-minded individuals, but anyone seeking to enhance their personal wellness.”
To learn more about cbdMD and their comprehensive line of U.S. grown, non-THC1 CBD oil products, please visit: http://www.cbdmd.com.
About cbdMD, Inc.
cbdMD, Inc. is one of the leading, most highly trusted, and most recognized cannabidiol (CBD) brands, whose current products include CBD tinctures, CBD capsules, CBD gummies, CBD topicals, CBD bath bombs and CBD pet products. cbdMD is also a proud partner of Bellator MMA and Life Time, Inc., and has one of the largest rosters of professional sports athletes who are part of “Team cbdMD.” To learn more about cbdMD and our comprehensive line of over 100 SKUs of U.S. produced, Non-THC CBD products, please visit http://www.cbdMD.com, follow cbdMD on Instagram and Facebook, or visit one of the 6,000 retail outlets that carry cbdMD products.
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including, without limitation, statements made with respect to the expansion of the consumer market for CBD products and our ability to increase our market share, our limited operating history, our ability to expand our business and significantly increase our revenues, our ability to effectively leverage our brand partnerships and sponsorships, our ability to effectively compete in our market, our ability to achieve our net sales guidance, and our ability to report profitable operations in the future. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2019 as filed with the Securities and Exchange Commission (the “SEC”) and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
1 Non-THC is defined as below the level of detection using validated scientific analytical tools.
Director of Investor Relations
Lauren Greene (PR), cbdMD, (843) 743-9999, [email protected]
John Weston (Investors), cbdMD, (704) 249-9515, [email protected]